Related references
Note: Only part of the references are listed.The CD47-SIRPα signalling system: its physiological roles and therapeutic application
Yoji Murata et al.
JOURNAL OF BIOCHEMISTRY (2014)
Bispecific antibodies with native chain structure
Romain Rouet et al.
NATURE BIOTECHNOLOGY (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
Bispecific antibodies rise again
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
Verena Rombach-Riegraf et al.
PLOS ONE (2014)
Bispecific antibodies for delivery into the brain
Ryan J. Watts et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
CDR-H3 Diversity Is Not Required for Antigen Recognition by Synthetic Antibodies
Helena Persson et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
Christoph Spiess et al.
NATURE BIOTECHNOLOGY (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Advances in bispecific biotherapeutics for the treatment of cancer
Chad May et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Christian Klein et al.
MABS (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Marketed therapeutic antibodies compendium
Janice M. Reichert
MABS (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Transfer of engineered biophysical properties between different antibody formats and expression systems
Jonas V. Schaefer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2012)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
By-passing in vitro screening-next generation sequencing technologies applied to antibody display and in silico candidate selection
U. Ravn et al.
NUCLEIC ACIDS RESEARCH (2010)
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
G. Wozniak-Knopp et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Rapid, simple and high yield production of recombinant proteins in mammalian cells using a versatile episomal system
Giovanni Magistrelli et al.
PROTEIN EXPRESSION AND PURIFICATION (2010)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens
C. Lloyd et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Bispecific antibodies: Molecules that enable novel therapeutic strategies
Nicolas Fischer et al.
PATHOBIOLOGY (2007)
Effects of protein aggregates: An immunologic perspective
Amy S. Rosenberg
AAPS JOURNAL (2006)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Biophysical properties of human antibody variable domains
S Ewert et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
A Knappik et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
